Company: INTS
Filing Date: 2025-04-25
Form Type: 424B4
Source: 0001628280-25-020056
Chunk: 20

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-25
Form: 424B4
Chunk 20
---
 related notes thereto, as well as “ Management’s Discussion and Analysis of Financial Condition and Results of Operations ” and the other financial information, incorporated by reference in this prospectus from our SEC filings, including our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q or our Current Reports on Form 8-K. The as adjusted information presented in the capitalization table below is unaudited.

|                                                                                                                                                                         |     | December 31, 2024                              |         |     |             |         |
|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:-----------------------------------------------|--------:|:----|:------------|--------:|
|                                                                                                                                                                         |     | -in thousands, except share and par value data |         |     |             |         |
|                                                                                                                                                                         |     | Actual                                         |         |     | As Adjusted |         |
| Cash and cash equivalents                                                                                                                                               |     | $                                              |   2,590 |     | $           |   4,486 |
| Shareholders’ equity                                                                                                                                                    |     |                                                |         |     |             |         |
| Common Stock; $0.0001 par value, 150,000,000 shares authorized, 15,122,873 shares issued and outstanding, actual, 18,256,206 shares issued and outstanding, as adjusted |     | $                                              |       2 |     | $           |       2 |
| Additional paid-in capital                                                                                                                                              |     | $                                              |  69,699 |     | $           |  71,594 |
| Accumulated deficit                                                                                                                                                     |     | $                                              | -66,783 |     | $           | -66,783 |
| Total shareholders’ equity                                                                                                                                              |     | $                                              |   2,918 |     | $           |   4,814 |
| Total capitalization                                                                                                                                                    |     | $                                              |   2,918 |     | $           |   4,814 |

The table and discussion above are based on 15,122,873 shares of Common Stock outstanding as of December 31, 2024, and excludes the following:

• 141,996 Shares of Common Stock issued after December 31, 2024;

• 2,587,129 shares of Common Stock issuable upon the exercise of outstanding stock options with a weighted average exercise price of $6.14 per share;

• 2,041,563 shares of Common Stock issuable upon the exercise of